Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Anaphylaxis to Pantoprazole: A Case Report and Prerequisite for Vigilant Prescribing Practises for Proton Pump Inhibitors

Author(s): Jerin James*, Jamuna Rani, Varadarajan Sathyanarayanan, Althab Begum and Syed Hussain Fayaz

Volume 17, Issue 1, 2022

Published on: 28 July, 2021

Page: [78 - 80] Pages: 3

DOI: 10.2174/1574886316666210728115356

Price: $65

Abstract

Background: Pantoprazole is a Proton Pump Inhibitor, commonly used by clinicians all over the world as a gastric acid synthesis inhibitor for a wide variety of gastrointestinal disorders. The efficacy and the safety of the drug are unsurmountable. PPIs are being prescribed nowadays for unapproved indications. It is one of the widely used medications in the world. Consequently, adverse events are commonly reported nowadays with proton pump inhibitors, and it is essential to improve physician awareness regarding judicious prescribing practice.

Objective: To report a case of anaphylaxis to pantoprazole, that occurred in a patient admitted with gastrointestinal complaints.

Case Summary: Within few minutes of intravenous infusion of pantoprazole, a 75-year-old female developed anaphylaxis. The adverse drug reaction was promptly diagnosed, and the patient was resuscitated.

Conclusion: It is imperative that clinicians should be aware of this adverse effect that might occur with pantoprazole and hence be more cautious while prescribing the drug, especially in the elderly.

Keywords: Anaphylaxis, case report, pantoprazole, proton pump inhibitor, WHO-UMC causality assessment scale, adverse drug reactions.

« Previous
[1]
Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW. The safety of appropriate use of over-the-counter proton pump inhibitors: An evidence-based review and delphi consensus. Drugs 2017; 77: 547-61.
[2]
Fuentes A, Pineda M, Venkata K. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharm 2018; 6(2): 43.
[3]
Clin Calc drug stats database. Available from:https://clincalc.com/DrugStats/
[4]
Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, et al. Proton-pump inhibitors among adults: A nationwide drug-utilization study. Therap Adv Gastroenterol 2018; 11: 1756284818777943.
[http://dx.doi.org/10.1177/1756284818777943]
[5]
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil 2018; 24(2): 182-96.
[6]
CARE Checklist Care case report guidelines. Available from:https://www.care-statement.org/checklist
[7]
WHO. The use of the WHO-UMC system for standardized case causality assessment. Why causality assessment? Available from:https://www.who.int/publications/m/item/WHO-causality-assessment
[8]
Acute hypersensitivity reaction related to use of pantoprazole lacking cross-reactivity with omeprazole case report. Available from:www.jcdr.net
[9]
Roche VF. American Association of Colleges of Pharmacy. The chemically elegant proton pump inhibitors. Am J Pharm Educ 2006; 70(5): 101.

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy